API
Talniflumate
KDMF APIs
Talniflumate
Korean name | 탈니플루메이트 |
|---|---|
Category | Central nervous system |
CAS No. | 66898-62-2 |
KDMF registration No. | 20100331-119-G-45-10(7) |
Manufacturer | Pen Tsao Chemical & Pharmaceutical Industry Co., Ltd. |
Specification | KP |
Product information
IUPAC Name | 3-oxo-1,3-dihydro-2-benzofuran-1-yl 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylate |
|---|---|
Description | Talniflumate, is an anti-inflammatory molecule studied and used as a mucin regulator in the treatment of cystic fibrosis, chronic obstructive pulmonary disease (COPD) and asthma. In addition, it is used in inflammatory conditions such as rheumatoid arthritis. Phase I trials with talniflumate for the treatment of cystic fibrosis and COPD were completed in August 2001, and phase II trials were performed in Ireland for the treatment of cystic fibrosis but this research has now been discontinued. Talniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan). |
Certificate of Analysis | If you need more information, please contact us. |
If you need additional documents such as specifications or certificates of analysis, please request them together with your inquiry. Our team will review and reply. (02-579-1056 · ace@acebiopharm.com)